Many readers of this blog will be interested to look through the data on the preliminary study design and diagnostic and baseline results of the randomized, phase III ProtecT trial that have just been reported in The Lancet Oncology.
Please understand that the current paper by Lane et al. (which is available on line as a full text article) does not yet provide us with comparative data on the outcomes of treatment with surgery, radiotherapy, and active surveillance. However, it does provide detailed information on the numbers of patients enrolled, the processes used to enroll them, and the processes by which they were assigned to specific treatment groups.
An associated editorial commentary by Roobol and Bokhorst (also available as the full text) discusses what we may be able to expect from this study in terms of results.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, ProtecT, radiotherapy, surgery |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply